Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Del Prete

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Molecular Therapy. Nucleic Acids|March 18, 2015
MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With SorafenibPaola Stiuso, Nicoletta Potenza, Angela Lombardi, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2009
Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case seriesLiliana Montella, Raffaele Addeo, Giovannella Palmieri, et al.
Clinical Drug Investigation|June 12, 2008
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational studyBarbara Silvestri, Elena Bandieri, Salvatore Del Prete, et al.
Leukemia & Lymphoma|April 12, 2003
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemiaDavid G Savage, Neil S Cohen, Charles S Hesdorffer, et al.
Breast (Edinburgh, Scotland)|June 17, 2020
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)Laura Orlando, Vito Lorusso, Francesco Giotta, et al.
Cancer Chemotherapy and Pharmacology|December 31, 2009
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. studySalvatore Del Prete, Liliana Montella, Michele Caraglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alphaPaolo Pedrazzoli, Antonio Farris, Salvatore Del Prete, et al.
Oncology Reports|April 2, 2011
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patientsDaniele Santini, Bruno Vincenzi, Vincenzo Adamo, et al.
Future Oncology (London, England)|December 17, 2013
Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient surveySalvatore Del Prete, Saverio Cinieri, Vito Lorusso, et al.
Journal of the National Cancer Institute|December 21, 2006
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition StudyRowan T Chlebowski, George L Blackburn, Cynthia A Thomson, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Molecular Therapy. Nucleic Acids|March 18, 2015
MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With SorafenibPaola Stiuso, Nicoletta Potenza, Angela Lombardi, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2009
Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case seriesLiliana Montella, Raffaele Addeo, Giovannella Palmieri, et al.
Clinical Drug Investigation|June 12, 2008
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational studyBarbara Silvestri, Elena Bandieri, Salvatore Del Prete, et al.
Leukemia & Lymphoma|April 12, 2003
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemiaDavid G Savage, Neil S Cohen, Charles S Hesdorffer, et al.
Breast (Edinburgh, Scotland)|June 17, 2020
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)Laura Orlando, Vito Lorusso, Francesco Giotta, et al.
Cancer Chemotherapy and Pharmacology|December 31, 2009
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. studySalvatore Del Prete, Liliana Montella, Michele Caraglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alphaPaolo Pedrazzoli, Antonio Farris, Salvatore Del Prete, et al.
Oncology Reports|April 2, 2011
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patientsDaniele Santini, Bruno Vincenzi, Vincenzo Adamo, et al.
Future Oncology (London, England)|December 17, 2013
Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient surveySalvatore Del Prete, Saverio Cinieri, Vito Lorusso, et al.
Journal of the National Cancer Institute|December 21, 2006
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition StudyRowan T Chlebowski, George L Blackburn, Cynthia A Thomson, et al.
Pageof 8